Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials

This publication has 62 references indexed in Scilit:

• Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
  JAMA, 2002
• Homocysteine Inhibits TNF-α-Induced Endothelial Adhesion Molecule Expression and Monocyte Adhesion via Nuclear Factor-κB Dependent Pathway
  Biochemical and Biophysical Research Communications, 2001
• Plasma total homocysteine concentration and the risk of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Studytpdel
  Journal of Internal Medicine, 2000
• Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: Results from the Third National Health and Nutrition Examination survey
  American Heart Journal, 2000
• Homocyst(e)ine impairs endocardial endothelial function
  Canadian Journal of Physiology and Pharmacology, 1999
• Hyperhomocysteinemia and Hypofibrinolysis in Young Adults With Ischemic Stroke
  Stroke, 1999
• Homocysteine and Cardiovascular Disease
  Annual Review of Medicine, 1998
• Homocysteine and coronary artery disease in French Canadian subjects: Relation with vitamins B12, B6, pyridoxal phosphate, and folate
  The American Journal of Cardiology, 1995
• Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells.
  Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
• Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine.
  Journal of Clinical Investigation, 1991